Genotyping cell-free DNA in lung cancer patients
Molecular Analysis of the Surnantant of Echoguidated Bronchoscopic Cytopunctions in Lung Cancer
University Hospital, Toulouse · NCT04624373
This study is testing a less invasive way to check for specific gene changes in lung cancer patients using a blood sample to help doctors make better treatment decisions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse (other) |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT04624373 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the genotyping of cell-free DNA obtained from the supernatant of EBUS-TBNA procedures in patients with non-small cell lung cancer (NSCLC). It aims to improve the accuracy of tumor genotyping by utilizing liquid biopsy techniques, which are less invasive than traditional tissue biopsies. The study addresses the challenge of limited tissue availability for multiplex analysis of various targetable mutations and markers, particularly in patients with advanced disease. By analyzing the molecular profile of tumors through minimally invasive methods, the study seeks to enhance treatment decision-making for lung cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are scheduled for an EBUS-TBNA due to suspected stage IV lung cancer or have stage IV NSCLC with specific mutations and resistance to targeted therapies.
Not a fit: Patients who refuse to participate or are under legal tutelage will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and timely identification of actionable mutations in lung cancer patients, improving treatment outcomes.
How similar studies have performed: Other studies have shown promise in using liquid biopsy techniques for genotyping in cancer, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years-old * Patients planned for an EBUS-TBNA for 1. Suspicion of stage IV lung cancer (PET+ mediastinal node(s)) (Cohort 1) 2. Stage IV NSCLC with an EGFR, BRAF, HER2, MET mutation or ALK, RET or ROS1 rearranged NSCLC and acquired resistance to targeted therapy (Cohort 2) * Performance status 0-3 * Informed consent Exclusion Criteria: * Refusal to participate * Patient under legal tutelage
Where this trial is running
Toulouse
- Nicolas Guibert — Toulouse, France (RECRUITING)
Study contacts
- Principal investigator: Nicolas Guibert — University Hospital, Toulouse
- Study coordinator: Nicolas Guibert, MD
- Email: guibert.n@chu-toulouse.fr
- Phone: 567778160
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, NSCLC, genotyping, liquid biopsy, cytology supernatant